Kevin Griffis brought his experience in government and politics to Planned Parenthood at the perfect time, leading the fight to protect birth control coverage under the Trump administration and destigmatizing abortion.
Pharma industry spent $57 million on lobbying in 2016; Humana, private equity firms to buy Kindred for $4 billion; price of old glaucoma drug skyrockets
A mini wave of state-level rule-making has thrust the issue of restrictions on pharma payments to medical professionals back into the spotlight.
Groups with PhRMA ties warn against drug-pricing proposals; patients learn how to be advocates; the U.K. will not cover Opdivo for head and neck cancer
BIO released a video explaining drug costs; the FDA commits to shorter generic approval process; Kaléo to launch EpiPen competitor
PhRMA brings on new members, Amgen partners with Daiichi Sankyo on biosimilar commercialization in Japan; Thomson Reuters to sell science unit
New PhRMA CEO issues policy strategy; study assess patient response to immuno-oncology drugs; Twitter may be an effective way to talk about clinical trials
PhRMA and BIO ramp up ad spend for presidential election year; Super Bowl Sunday features three pharma ads; Pfizer solidifies leadership team
PhRMA hires Ubl as CEO; two drugs report superior results in kidney-cancer trials compared to the standard of care; Novo Nordisk's shares rise on Tresiba approval
Physicians criticize pricing of Orkambi, Vertex's new cystic-fibrosis drug; the EU approves Amgen's PCSK9 inhibitor Repatha; PhRMA boosts lobbying spending in the second quarter
The FDA approves generic Copaxone; AstraZeneca's experimental lung-cancer drug demonstrates that it can delay disease progression; PhRMA CEO John Castellani to step down